$41MSeries D, 19 May 2026
Series D funds the REMODEL II pivotal trial, commercial launch and a coronary version of its IVL system.
- Amount
- $41M
- Stage
- Series D
- Announced
- 19 May 2026
- Lead
- U.S. Venture Partners
- Other investors
- Astoria Health Investors
- Use of funds
- Series D funds the REMODEL II pivotal trial, commercial launch and a coronary version of its IVL system.
- Checked
- Announced by the company
- Sources
- Cagent Vascular closes $41M Series D businesswire.com
Cagent Vascular closes $41M Series D pulse2.com